Total Payments
$30,378
2024 Payments
$22,363
Companies
26
Transactions
273
Medicare Patients
16,221
Medicare Billing
$1.8M
Payment Breakdown by Category
Other$18,250 (60.1%)
Food & Beverage$6,139 (20.2%)
Consulting$4,521 (14.9%)
Travel$1,359 (4.5%)
Education$109.24 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $10,925 | 6 | 36.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,325 | 6 | 24.1% |
| Food and Beverage | $6,139 | 252 | 20.2% |
| Consulting Fee | $4,521 | 4 | 14.9% |
| Travel and Lodging | $1,359 | 2 | 4.5% |
| Education | $109.24 | 3 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CALLIDITAS THERAPEUTICS US INC. | $12,792 | 18 | $0 (2024) |
| Travere Therapeutics, Inc. | $8,529 | 34 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,148 | 14 | $0 (2024) |
| Amgen Inc. | $2,592 | 45 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,153 | 49 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $361.36 | 14 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $273.49 | 21 | $0 (2024) |
| Horizon Therapeutics plc | $265.96 | 16 | $0 (2023) |
| OPKO Pharmaceuticals, LLC | $210.47 | 12 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $187.11 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,363 | 89 | CALLIDITAS THERAPEUTICS US INC. ($12,690) |
| 2023 | $6,254 | 94 | Novartis Pharmaceuticals Corporation ($2,779) |
| 2022 | $891.43 | 47 | Amgen Inc. ($227.09) |
| 2021 | $635.85 | 36 | Mallinckrodt Hospital Products Inc. ($140.17) |
| 2020 | $97.02 | 5 | Mallinckrodt Hospital Products Inc. ($41.44) |
| 2019 | $122.17 | 1 | AstraZeneca Pharmaceuticals LP ($122.17) |
| 2018 | $14.63 | 1 | Roche Diagnostics Corporation ($14.63) |
All Payment Transactions
273 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $950.00 | General |
| Category: Nephrology | ||||||
| 12/04/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| 11/05/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $225.00 | General |
| Category: Immunology | ||||||
| 10/30/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $2,850.00 | General |
| Category: Nephrology | ||||||
| 10/24/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $2,850.00 | General |
| Category: Nephrology | ||||||
| 10/23/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Nephrology | ||||||
| 10/17/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Nephrology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: Immunology | ||||||
| 10/01/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $34.39 | General |
| Category: Nephrology | ||||||
| 09/27/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Travel and Lodging | Cash or cash equivalent | $977.32 | General |
| Category: Nephrology | ||||||
| 09/27/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $360.00 | General |
| Category: Nephrology | ||||||
| 09/24/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Education | In-kind items and services | $75.99 | General |
| Category: IMMUNOLOGY | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/23/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: Nephrology | ||||||
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/18/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: CRITICAL CARE | ||||||
| 09/16/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $23.98 | General |
| 09/06/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| 09/05/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $27.66 | General |
| 09/05/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: Obesity | ||||||
| 09/04/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $28.94 | General |
| 09/04/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $4.31 | General |
| 08/29/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/28/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $31.71 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/27/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 3,765 | 7,277 | $1.1M | $408,899 |
| 2022 | 23 | 3,343 | 6,660 | $1.1M | $412,129 |
| 2021 | 29 | 4,576 | 8,455 | $1.2M | $507,007 |
| 2020 | 28 | 4,537 | 8,745 | $1.1M | $430,446 |
Total Patients
16,221
Total Services
31,137
Medicare Billing
$1.8M
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 68 | 391 | $269,008 | $112,544 | 41.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 626 | 1,286 | $318,928 | $86,052 | 27.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 382 | 1,179 | $183,924 | $77,194 | 42.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 222 | 234 | $80,028 | $32,562 | 40.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 114 | 269 | $62,946 | $26,560 | 42.2% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 40 | 67 | $38,324 | $16,094 | 42.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 115 | 115 | $37,490 | $14,137 | 37.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 81 | $28,188 | $7,725 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $11,180 | $4,423 | 39.6% |
| 80069 | Kidney function blood test panel | Office | 2023 | 246 | 440 | $7,920 | $3,744 | 47.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 32 | 35 | $9,030 | $3,395 | 37.6% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 70 | 73 | $5,986 | $2,953 | 49.3% |
| 90970 | Dialysis services, per day, less than full month service (20 years or older) | Office | 2023 | 28 | 359 | $6,462 | $2,811 | 43.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 209 | 350 | $5,600 | $2,664 | 47.6% |
| 83735 | Magnesium level | Office | 2023 | 222 | 388 | $5,432 | $2,549 | 46.9% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 285 | 442 | $4,420 | $2,245 | 50.8% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 14 | 14 | $7,476 | $2,093 | 28.0% |
| G2013 | Extensive (75 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 | Office | 2023 | 11 | 11 | $4,510 | $1,912 | 42.4% |
| 84100 | Phosphate level | Office | 2023 | 219 | 384 | $3,840 | $1,786 | 46.5% |
| 84156 | Total protein level, urine | Office | 2023 | 277 | 415 | $3,320 | $1,494 | 45.0% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 290 | 448 | $2,688 | $1,393 | 51.8% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 84 | 105 | $2,730 | $1,378 | 50.5% |
| 82306 | Vitamin d-3 level | Office | 2023 | 17 | 17 | $1,020 | $493.17 | 48.4% |
| 84550 | Uric acid level, blood | Office | 2023 | 67 | 85 | $850.00 | $376.55 | 44.3% |
| 84300 | Urine sodium level | Office | 2023 | 22 | 33 | $330.00 | $163.68 | 49.6% |
About Dr. Marc Richards, MD
Dr. Marc Richards, MD is a Nephrology healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2008. The National Provider Identifier (NPI) number assigned to this provider is 1760643282.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Richards, MD has received a total of $30,378 in payments from pharmaceutical and medical device companies, with $22,363 received in 2024. These payments were reported across 273 transactions from 26 companies. The most common payment nature is "Honoraria" ($10,925).
As a Medicare-enrolled provider, Richards has provided services to 16,221 Medicare beneficiaries, totaling 31,137 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Internal Medicine
- Location Boca Raton, FL
- Active Since 06/18/2008
- Last Updated 10/09/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760643282
Products in Payments
- TARPEYO (Drug) $12,792
- TAVNEOS (Drug) $1,875
- FARXIGA (Drug) $618.25
- LOKELMA (Drug) $534.86
- KRYSTEXXA (Biological) $384.44
- Parsabiv (Drug) $357.23
- ACTHAR (Biological) $309.76
- Fabhalta (Drug) $277.77
- Kerendia (Drug) $273.49
- JARDIANCE (Drug) $217.73
- RAYALDEE (Drug) $210.47
- JYNARQUE (Drug) $176.88
- Aranesp (Biological) $155.25
- BENLYSTA (Biological) $147.14
- Veltassa (Drug) $110.63
- LUPKYNIS (Drug) $99.38
- Tavneos (Drug) $86.67
- TERLIVAZ (Drug) $51.60
- Velphoro (Drug) $50.14
- Ozempic (Drug) $42.55
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Boca Raton
Jared Jaffe, Do, DO
Nephrology — Payments: $16,910
Nephrology $16,910
John Panos, Md, MD
Nephrology — Payments: $4,533
Nephrology $4,533
Craig Stemmer, Md, MD
Nephrology — Payments: $2,619
Nephrology $2,619
Dr. Rajesh Agarwala, M.d, M.D
Nephrology — Payments: $1,101
Nephrology $1,101
Dr. Mary Sifain, Do, DO
Nephrology — Payments: $854.11
Nephrology $854.11
Eric Lazar, Md, MD
Nephrology — Payments: $542.65
Nephrology $542.65